Fengzhi Li
Associate Professor
Department of Pharmacology & Therapeutics
Roswell Park Cancer Institute
United States of America
Biography
Dr. Fengzhi Li works as an Associate Professor of Oncology in the Department of Pharmacology & Therapeutics at Roswell Park Cancer Institute. His research interests include: I was initially involved in characterization of the anti-apoptotic protein survivin during my postdoctoral studies at Yale Medical School (Li et al., Nature, 396: 580-584, 1998; Li et al., Nature Cell Biol, 1: 461-466, 1999). Survivin is a novel member in the inhibitor of apoptosis (IAP) family and is a treatment (radiation, chemotherapy) resistant factor. Survivin is aberrantly expressed in all types of cancer, while undetectable or with very low level expression in normal tissues.
Research Interest
Anti-cancer drug discovery, development and mechanism of action studies, Mechanisms of drug resistance and how to overcome them, Targeted cancer treatment and personalized/precision medicine through NGS technologies
Publications
-
Ling X, Li F, (2013) An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI). American Journal of Translational Research 3: 139-154
-
Zhao J, Ling X, Cao S, Liu X, Li F, et al. (2014) Antitumor activity of FL118, a survivin, Mcl-1, XIAP, cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration. Molecular Pharmaceutics 11: 457-467
-
Ling X, Xu C, Fan C, Zhong K, Li F, et al. (2014) FL118 Induces p53-Dependent Senescence in Colorectal Cancer Cells by Promoting Degradation of MdmX, Cancer Research 74: 7487-7497
